requirements for tirzepatide BMI Guidelines Eligibility Expert GLP-1 Tirzepatide Weight Loss

GLP-1 drugs may reshape brain's dopamine reward system Beyond weight loss, research is pointing to broader effects on the brain

Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease

Understanding the Gauge (G) The term gauge refers to the diameter of the needle

For some individuals, long-term treatment may make sense

Who Should Not Use Tirzepatide

To help in the treatment of cardiovascular problems such as angina pectoris, cardiac arrhythmia and congestive heart failure